×

Developing Best-in-Class Medicine. Improving Lives.

Rethinking Treatments for Oncology Care

Learn More

Reimagining Acute Care

Learn More

About Heron

At Heron, we are unwavering in our commitment to improve the lives of patients. We aim to advance the therapeutic standard of care for patients through a portfolio of best-in-class therapies that bring together our innovative science and technologies with well-known pharmacology to deliver medicines that matter.

Solution Spotlight

At Heron, we understand what is at stake for patients, their caregivers, and families, which is why we are laser-focused on providing solutions that can address unmet medical needs so they can spend more time doing the things that matter with the people who matter.

Opiod Crisis

How the Surgical Setting Contributes to the Opioid Crisis

In the United States each year, 50 million surgeries are performed and the continuing over-reliance on postoperative opioids fuels the crisis by both exposing opioid-naïve patients to narcotics and by leaving hundreds of millions of leftover pills hiding in our community medicine cabinets.1-2

Read More

View References

  1. Brummett CM, et al. New persistent opioid use after minor and major surgical procedures in US adults. JAMA Surg. 2017;152(6):e170504. doi:10.1001/jamasurg.2017.0504
  2. Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL. Prescription Opioid Analgesics Commonly Unused After Surgery: A Systematic Review. JAMA Surg. 2017;152(11):1066–1071. doi:10.1001/jamasurg.2017.0831

Product Pipeline

Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.

SUSTOL® for Chemotherapy-Induced Nausea and Vomiting Prevention (CINV):
U.S. FDA approved as a subcutaneous injection

CINVANTI® for CINV:
U.S. FDA approved as a 30-minute intravenous (IV) infusion and a 2-minute IV injection

ZYNRELEF for Postoperative Pain Management:

  • Marketing Applications Under Review in Canada and Approved in the U.S. and 31 European Countries

HTX-019 for Postoperative Nausea and Vomiting (PONV):

  • Bioequivalence of HTX-019 as a 30-second IV injection demonstrated to approved oral dose of aprepitant for PONV
  • U.S. NDA planned for PONV prevention in 4Q2021

HTX-034 for Postoperative Pain Management

Phase 2 clinical study ongoing for postoperative pain via local application into the surgical site

Learn More
investors

Investor Resources

At Heron, our mission is to improve the lives of patients by developing best-in-class medicines that address unmet medical needs. We are developing novel, patient-focused solutions that apply our innovative science and technologies to already-approved pharmacological agents.

 

Learn More

Recent News

July 21 2021

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

Read More

July 06 2021

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

Read More

July 01 2021

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours

Read More

May 25 2021

Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference

Read More
header-careers

Careers

We’re looking for people who share our passion and purpose for improving lives of patients.

Learn More

Sign-Up for Email Updates

Receive news and updates on Heron’s latest innovations.

Dev Tool:

Request: None
Matched Rewrite Rule: None
Matched Rewrite Query: None
Loaded Template: front-page.php